Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
The Hypotensive Effect of Metformin in Hypertensive Patients.
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 92
- Registration Number
- NCT02072382
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 192
- Registration Number
- NCT02072096
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States
🇺🇸Carolina Health Specialists, Myrtle Beach, South Carolina, United States
Endogenous Opioid Activity and Affective State in Insulin Resistant Women
- Conditions
- DepressionInsulin ResistanceMetabolic Syndrome
- Interventions
- Drug: PlaceboDrug: Metformin
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 42
- Registration Number
- NCT02069379
- Locations
- 🇺🇸
University of Michigan Medical School, Ann Arbor, Michigan, United States
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 374
- Registration Number
- NCT02068443
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
- Conditions
- Recurrent Uterine Corpus CarcinomaEndometrial AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaStage III Uterine Corpus Cancer AJCC v7Stage IIIA Uterine Corpus Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7Stage IVA Uterine Corpus Cancer AJCC v7
- Interventions
- Drug: CarboplatinOther: Laboratory Biomarker AnalysisDrug: Metformin HydrochlorideDrug: PaclitaxelOther: Placebo AdministrationOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 469
- Registration Number
- NCT02065687
- Locations
- 🇺🇸
Novant Health Cancer Institute - Wilkesboro, Wilkesboro, North Carolina, United States
🇺🇸Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸AnMed Health Cancer Center, Anderson, South Carolina, United States
Efficacy Study of Metformin Glycinate on Postprandial Lipemia
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 72
- Registration Number
- NCT02064881
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, México, Distrito Federal, Mexico
Metformin vs Conjugated Linoleic Acid and an Intervention Program With Healthy Habits in Obese Children
- Conditions
- Obesity
- Interventions
- Dietary Supplement: Conjugated Linoleic AcidDrug: PlaceboDrug: metforminBehavioral: Healthy habits program
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 120
- Registration Number
- NCT02063802
- Locations
- 🇲🇽
General Hospital of Mexico, Mexico, Distrito Federal, Mexico
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
- Conditions
- Cushing's DiseaseAcromegaly
- Interventions
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 249
- Registration Number
- NCT02060383
- Locations
- 🇺🇸
LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States
🇺🇸Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States
🇺🇸East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Insulin glargine/lixisenatide Fixed Ratio CombinationDrug: Insulin glargine (HOE901)Drug: Lixisenatide (AVE0010)Drug: Metformin
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1170
- Registration Number
- NCT02058147
- Locations
- 🇺🇸
Investigational Site Number 840023, Tempe, Arizona, United States
🇺🇸Investigational Site Number 840067, Santa Ana, California, United States
🇺🇸Investigational Site Number 840089, Atlanta, Georgia, United States
The Role of Metformin and Colesevelam in Human GLP-1 Secretion
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 12
- Registration Number
- NCT02050074
- Locations
- 🇩🇰
Diabetes Research Division, Department of Medicine, Gentofte Hospital, Hellerup, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.